Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior

ConditionBreast Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorUNC Lineberger Comprehensive Cancer Center

About this trial

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at tissue and blood samples from women with locally advanced or metastatic breast cancer

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Participants will be selected from those individuals receiving diagnostic and treatment related biopsies at the University of North Carolina at Chapel Hill.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

biologic sample preservation procedure
Other intervention
approximately 16-20 milligrams of tumor tissue per core will be obtained for research purposes.
laboratory biomarker analysis
Other intervention
Evaluation of biomarkers will occur as questions are asked in subsequent correlative studies.
biopsy
Procedure/Surgery
cancer tissue will be taken from the primary breast cancer site as well as the metastatic tumor sites. Two tubes of whole blood will also be collected.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

Generation of a biorepository for current and future correlative research studies

Time frame

Diagnosis, between treatments,7-14 days after start of treatment and at time of definitive therapy

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

UNC Lineberger Comprehensive Cancer Center

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov

Apply now